Oncological Benefits of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients With T3-4 Gastric Cancer Cyt-

Stomach cancer is recognized as the third leading cause of death of cancer patients worldwide. Despite the radical treatment carried out, the progression of gastric cancer occurs in 30-40% of patients. The most common type of tumor progression of this localization is peritoneal carcinomatosis. When peritoneal carcinomatosis occurs, the median survival of patients does not exceed 3 months, the overall survival is no more than 6 months. Unfortunately, when peritoneal carcinomatosis occurs, palliative chemotherapy remains the only treatment option. The modern strategy for the prevention and treat

Trial Details

NCT ID
NCT04595929
Phase
NA
Sponsor
St. Petersburg State Pavlov Medical University
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • Staging laparoscopy
  • 5-Fluorouracil
  • Leucovorin
  • Oxaliplatin
  • Docetaxel
  • Radical surgery
Locations (sample)
  • Saint Petersburg, Russia|59.93863,30.31413

Key Eligibility Criteria

  • Histologically confirmed, medically operable, resectable stomach adenocarcinoma (cT3-4, any N category, M0).
  • No preceding cytotoxic or targeted therapy.
  • No prior partial or complete tumor resection.
  • Female and male patient ≥ 18 and ≤ 75 years. Female patient with childbearing potential needs to have a negative pregnancy test within 7 days prior…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →